Abstract:Background Paeoniflorin (PF), the main active glucoside of Paeonia Lactiflora, has many pharmacological activities, such as inhibition of vasodilation, hypoglycemia, and immunomodulation. Although the current evidence has suggested the therapeutic effects of PF on diabetic nephropathy (DN), its potential mechanism of action is still unclear. Purpose A systematic review and meta-analysis of the existing literature on paeoniflorin treatment in DN animal models was performed to evaluate the efficacy and mechanism of PF in DN animal models. Methods The risk of bias in each study was judged using the CAMARADES 10-item quality checklist with the number of criteria met varying from 4 / 10 to 7 / 10, with an average of 5.44. From inception to July 2022, We searched eight databases. We used the Cochrane Collaboration’s 10-item checklist and RevMan 5.3 software to assess the risk of bias and analyze the data. Three-dimensional dose/time-effect analyses were conducted to examine the dosage/time-response relations between PF and DN. Results Nine animal studies were systematically reviewed to evaluate the effectiveness of PF in improving animal models of DN. Meta-analysis data and intergroup comparisons indicated that PF slowed the index of mesangial expansion and tubulointerstitial injury, 24-h urinary protein excretion rate, expression of anti-inflammatory mediators (mRNA of MCP-1, TNF-α, iNOS, and IL-1 β), and expression of immune downstream factors (P-IRAK1, TIRF, P-IRF3, MyD88, and NF-κBp-p65). Furthermore, modeling methods, animal species, treatment duration, thickness of tissue sections during the experiment, and experimental procedures were subjected to subgroup analyses. Conclusion The present study demonstrated that the reno-protective effects of PF were associated with its inhibition on macrophage infiltration, reduction of inflammatory mediators, and immunomodulatory effects. In conclusion, PF can effectively slow down the progression of DN and hold promise as a protective drug for the treatment of DN. Due to the low bioavailability of PF, further studies on renal histology in animals are urgently needed. We therefore recommend an active exploration of the dose and therapeutic time frame of PF in the clinic and in animals. Moreover, it is suggested to actively explore methods to improve the bioavailability of PF to expand the application of PF in the clinic.

Paeonol Ameliorates Diabetic Renal Fibrosis Through Promoting the Activation of the Nrf2/ARE Pathway Via Up-Regulating Sirt1

Paeonol Attenuates High Glucose-Induced Expression of FN and ICAM-1 by Promoting the Activation of Nrf2/ARE Pathway Via Upregulation of Sirt1 in GMCs

Paeonol Ameliorates Glucose and Lipid Metabolism in Experimental Diabetes by Activating Akt

Renal Protective Effect of Paeoniflorin by Inhibition of JAK2/STAT3 Signaling Pathway in Diabetic Mice.

Antidiabetic nephropathy effects of paeonol on streptozotocin induced diabetic rats

Protective effect of paeoniflorin in diabetic nephropathy: A preclinical systematic review revealing the mechanism of action

Paeoniflorin Ameliorates Macrophage Infiltration and Activation by Inhibiting the TLR4 Signaling Pathway in Diabetic Nephropathy.

Polydatin Promotes Nrf2-ARE Anti-Oxidative Pathway Through Activating Sirt1 to Resist AGEs-induced Upregulation of Fibronetin and Transforming Growth Factor-Β1 in Rat Glomerular Messangial Cells.

Paeoniflorin Protects Diabetic Mice Against Myocardial Ischemic Injury Via the Transient Receptor Potential Vanilloid 1/calcitonin Gene-Related Peptide Pathway.

CAPE-pNO2 Ameliorated Diabetic Nephropathy Through Regulating the Akt/NF-κB/ Inos Pathway in STZ-induced Diabetic Mice

Polydatin Promotes Nrf2-ARE Anti-Oxidative Pathway Through Activating CKIP-1 to Resist HG-induced Up-Regulation of FN and ICAM-1 in GMCs and Diabetic Mice Kidneys.

Paeoniflorin Attenuates Incipient Diabetic Nephropathy in Streptozotocin-Induced Mice by the Suppression of the Toll-like Receptor-2 Signaling Pathway

(+)-Catechin ameliorates diabetic nephropathy injury by inhibiting endoplasmic reticulum stress-related NLRP3-mediated inflammation

Proanthocyanidin offers protection against diabetic nephropathy: elucidation of its mechanism of action using animal models

Phloretin Ameliorates Diabetic Nephropathy by Inhibiting Nephrin and Podocin Reduction Through a Non-Hypoglycemic Effect

Hypoglycemic and Antioxidant Activities of Paeonol and Its Beneficial Effect on Diabetic Encephalopathy in Streptozotocin-Induced Diabetic Rats (vol 16, pg 577, 2013)

Betacyanins Attenuates Diabetic Nephropathy in Mice by Inhibiting Fibrosis and Oxidative Stress Via the Improvement of Nrf2 Signaling

Hypoglycemic and Antioxidant Activities of Paeonol and Its Beneficial Effect on Diabetic Encephalopathy in Streptozotocin-Induced Diabetic Rats

Fraxin Promotes the Activation of Nrf2/ARE Pathway via Increasing the Expression of Connexin43 to Ameliorate Diabetic Renal Fibrosis

Periplaneta Americana Extract May Attenuate Renal Fibrosis through Inhibiting Janus Tyrosine Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway

Polydatin Attenuates AGEs-induced Upregulation of Fibronectin and ICAM-1 in Rat Glomerular Mesangial Cells and Db/db Diabetic Mice Kidneys by Inhibiting the Activation of the SphK1-S1P Signaling Pathway